Abstract

Oncolytic virotherapies based on adenovirus 5 (Ad5) hold promise as adjunctive cancer therapies; however, their efficacy when delivered systemically is hampered by poor target cell specificity and preexisting anti-Ad5 immunity. Ovarian cancer represents a promising target for virotherapy, since the virus can be delivered locally into the peritoneal cavity. Both epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor 1 (FGFR1) are overexpressed in the majority of human tumors, including ovarian cancer. To generate adenoviral vectors with improved tumor specificity, we generated a panel of Ad5 vectors with altered tropism for EGFR and FGFR, rather than the natural Ad5 receptor, hCAR. We have included mutations within AB loop of the viral fiber knob (KO1 mutation) to preclude interaction with hCAR, combined with insertions in the HI loop to incorporate peptides that bind either EGFR (peptide YHWYGYTPQNVI, GE11) or FGFR1 (peptides MQLPLAT, M*, and LSPPRYP, LS). Viruses were produced to high titers, and the integrity of the fiber protein was validated by Western blotting. The KO1 mutation efficiently ablated hCAR interactions, and significantly increased transduction was observed in hCARlow/EGFRhigh cell lines using Ad5.GE11, while transduction levels using Ad5.M* or Ad5.LS were not increased. In the presence of physiological concentrations of human blood clotting factor X (hFX), significantly increased levels of transduction via the hFX-mediated pathway were observed in cell lines, but not in primary tumor cells derived from epithelial ovarian cancer (EOC) ascites samples. Ad5-mediated transduction of EOC cells was completely abolished by the presence of 2.5% serum from patients, while, surprisingly, incorporation of the GE11 peptide resulted in significant evasion of neutralization in the same samples. We thus speculate that incorporation of the YHWYGYTPQNVI dodecapeptide within the fiber knob domain may provide a novel means of circumventing preexisting Ad5 immunity that warrants further investigation.

Highlights

  • Ovarian cancer remains the fourth most common cancer in women in the United Kingdom, with *7000 women diagnosed annually with the disease, and a mortality rate of *4500 per annum

  • We report the successful production and in vitro characterization of a suite of six novel, potentially tumortargetable recombinant adenovirus 5 (Ad5) vectors. We evaluate their ability to transduce cancer cell lines in vitro, and evaluate the effect of human blood clotting factor X (hFX) on their capacity to transduce both cell lines and primary, epithelial ovarian cancer (EOC) cells isolated from ascites of patients with ovarian cancer

  • Ovarian cancer represents an ideal avenue for localized delivery of oncolytic virotherapies via the peritoneal route, circumventing some of the difficulties of delivery via the intravenous route

Read more

Summary

Introduction

Ovarian cancer remains the fourth most common cancer in women in the United Kingdom, with *7000 women diagnosed annually with the disease, and a mortality rate of *4500 per annum. Despite recent therapeutic advances with the role of neoadjuvant chemotherapy, changes in chemotherapy scheduling, bevacizumab,[1] and PARP inhibitors,[2] the outlook for advanced ovarian cancer patients remains poor, with only small improvement in 5-year survival statistics over the last 20 years. Standard treatments remain surgery and/or chemotherapy, and despite good initial responses to chemotherapy, many tumors rapidly develop resistance and progress into aggressive, platinum-resistant forms. There is a pressing need to establish new therapeutics to combat the disease. Oncolytic virotherapy is a promising adjunct to conventional drug-based strategies for effective cancer therapies, and has progressed into late-phase clinical trials.[3] An oncolytic herpes virus expressing GM-CSF has demonstrated

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call